No Data
On January 15, BRII-B (02137.HK) spent 1.7886 million Hong Kong dollars to repurchase 1.6 million shares.
Gelonghui, January 15 - BRII-B (02137.HK) announced that on January 15, it spent 1.7886 million Hong Kong dollars to repurchase 1.6 million shares, with a repurchase price of 1.1-1.14 Hong Kong dollars per share.
On January 14, BRII-B (02137.HK) spent 1.089 million Hong Kong dollars to repurchase 0.98 million shares.
Gelonghui, January 14 - BRII-B (02137.HK) announced that on January 14, it spent 1.089 million Hong Kong dollars to repurchase 0.98 million shares.
Hong Kong stocks movement | BRII-B (02137) rose over 8% in the morning session after announcing a 60 million Hong Kong dollars buyback plan. The company acquired the intellectual property of BRII-179.
BRII-B (02137) rose over 8% in the morning session, and as of the time of reporting, it has increased by 5%, trading at 1.05 HKD, with a transaction volume of 1.5278 million HKD.
BRII-B (02137.HK) has entered into an asset acquisition agreement for BRII-179 and PreHevbri.
Gelonghui reported on December 31st that BRII-B (02137.HK) announced that on December 31, 2024, the company agreed to the following transactions: (i) entering into an acquisition of BRII-179 and PreHevbri assets with the VBI contracting party and the K2 contracting party, whereby K2 agreed to designate the company as the agent for purchasing and acquiring from the VBI contracting party, and the VBI contracting party agreed to transfer, assign, and grant to the company the rights, ownership, and interests in all assets acquired by BRII-B from the date of delivery; and (ii) PreHevbri licensing.
Express News | Brii Biosciences Ltd - Co & VBI to Terminate Agreements Announced on Feb 14
Express News | Brii Bio Announces Signing of Asset Purchase Agreements Acquiring Brii-179 Ip Rights and Completed Patient Enrollment for Enrich Study
